Each vial contains 5mg of lyophilized BPC-157
Most patients tolerate peptide therapy well, especially when its customized to their bodys needs
You can also read our guide to Vitamin B12 optimization to learn more
Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
Ready to explore if BPC-157 peptide therapy is right for you
Proceedings of the New Zealand Society of Animal Production, 62, 307-310